Use of formative research in developing a knowledge translation approach to rotavirus vaccine introduction in developing countries

Evan Simpson, Scott Wittet, Josefina Bonilla, Kateryna Gamazina, Laura Cooley, Jennifer L Winkler, Evan Simpson, Scott Wittet, Josefina Bonilla, Kateryna Gamazina, Laura Cooley, Jennifer L Winkler

Abstract

Background: Rotavirus gastroenteritis is the leading cause of diarrheal disease mortality among children under five, resulting in 450,000 to 700,000 deaths each year, and another 2 million hospitalizations, mostly in the developing world. Nearly every child in the world is infected with rotavirus at least once before they are five years old. Vaccines to prevent rotavirus or minimize its severity are now becoming available, and have already been introduced into the public vaccine programs of several Latin American countries. The World Health Organization (WHO) has made rotavirus vaccine introduction in developing countries a high priority. The WHOs Guidelines for Vaccine Introduction indicates that a key determinant to achieving vaccine introduction is the public health priority of the disease, suggesting that where the disease is not a priority uptake of the vaccine is unlikely. WHO recommends conducting a qualitative analysis of opinions held by the public health community to determine the perceptions of the disease and the priority given to the vaccine.

Methods: This paper presents the formative research results of a qualitative survey of public health providers in five low- and middle-income countries to determine if and to what degree rotavirus is perceived to be a problem and the priority of a vaccine. Open-ended surveys were carried out through focus group discussions and one-on-one interviews.

Results: Researchers discovered that in all five countries knowledge of rotavirus was extremely low, and as a result was not considered a high priority. However, diarrhea among young children was considered a high priority among public health providers in the three poorest countries with relatively high levels of child mortality: India, Indonesia, and Nicaragua.

Conclusion: In the poorest countries, advocacy and communication efforts to raise awareness about rotavirus sufficient for prioritization and accelerated vaccine introduction might benefit from a knowledge translation approach that delivers information and evidence about rotavirus through the broader context of diarrheal disease control, an existing priority, and including information about other new interventions, specifically low-osmolarity oral rehydration solution and zinc treatment.

Figures

Figure 1
Figure 1
Enhanced Diarrheal Disease Control Framework.

References

    1. Kosek M, Bern C, Guerrant RL. The global burden of diarrhoeal disease, as estimated from studies published between 1992 and 2000. Bull World Health Organ. 2003;81:197–204.
    1. Parashar UD, Gibson CJ, Bresse JS, Glass RI. Rotavirus and severe childhood diarrhea. Emerg Infect Dis. 2006;12:304–306.
    1. Velazquez FR, Matson DO, Calva JJ, Guerrero L, Morrow AL, Carter-Campbell S, Glass RI, Estes MK, Pickering LK, Ruiz-Palacios GM. Rotavirus infections in infants as protection against subsequent infections. N Engl J Med. 1996;335:1022–1028. doi: 10.1056/NEJM199610033351404.
    1. Organization WH. Weekly Epidemiologic Record. Vol. 78. World Health Organization; 2003. Rotavirus vaccines, an update; pp. 2–3.
    1. GAVI Alliance GAVI and the Vaccine Fund announce $60 million boost to accelerate development of lifesaving vaccine. 2003
    1. Vesikari T, Matson DO, Dennehy P, Van Damme P, Santosham M, Rodriguez Z, Dallas MJ, Heyse JF, Goveia MG, Black SB, Shinefield HR, Christie CD, Ylitalo S, Itzler RF, Coia ML, Onorato MT, Adeyi BA, Marshall GS, Gothefors L, Campens D, Karvonen A, Watt JP, O'Brien KL, DiNubile MJ, Clark HF, Boslego JW, Offit PA, Heaton PM. Safety and efficacy of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine. N Engl J Med. 2006;354:23–33. doi: 10.1056/NEJMoa052664.
    1. Ruiz-Palacios GM, Perez-Schael I, Velazquez FR, Abate H, Breuer T, Clemens SC, Cheuvart B, Espinoza F, Gillard P, Innis BL, Cervantes Y, Linhares AC, Lopez P, Macias-Parra M, Ortega-Barria E, Richardson V, Rivera-Medina DM, Rivera L, Salinas B, Pavia-Ruz N, Salmeron J, Ruttimann R, Tinoco JC, Rubio P, Nunez E, Guerrero ML, Yarzabal JP, Damaso S, Tornieporth N, Saez-Llorens X, Vergara RF, Vesikari T, Bouckenooghe A, Clemens R, De Vos B, O'Ryan M. Safety and efficacy of an attenuated vaccine against severe rotavirus gastroenteritis. N Engl J Med. 2006;354:11–22. doi: 10.1056/NEJMoa052434.
    1. Organization WH. Weekly Epidemiologic Record. Vol. 1. World Health Organization; 2006. Conclusions and recommendations from the Strategic Advisory Group of Experts to the Department of Immunizatoin, Vaccines and Biologicals; pp. 8–8.
    1. Alliance GAVI. Rotavirus Vaccine. GAVI Alliance. 2007.
    1. Organization WH. Vaccine Introduction Guidelines. 2005.
    1. Newes G, Helitzer DL, Caulfield LE, Brown KH. Health Education Research. Vol. 15. Oxford University Press; 2000. Theory and practice: applying the ecological model to formative research for a WIC training program in New York State; pp. 283–291.
    1. ProMED-Mail Viral Gastroenteritis Update 2005. 2005.
    1. Bhutta ZA, Black RE, Brown KH, Gardner JM, Gore S, Hidayat A, Khatun F, Martorell R, Ninh NX, Penny ME, Rosado JL, Roy SK, Ruel M, Sazawal S, Shankar A. Prevention of diarrhea and pneumonia by zinc supplementation in children in developing countries: pooled analysis of randomized controlled trials. Zinc Investigators' Collaborative Group. J Pediatr. 1999;135:689–697. doi: 10.1016/S0022-3476(99)70086-7.
    1. Glass RI, Parashar UD, Bresee JS, J G, Turcios R JB. Rotavirus Vaccines. In: CA DQ, editor. Vaccines: Preventing Disease and Protecting Health. Scientific and Technical Publication 593. Washington DC., Pan American Health Organization; 2004. pp. 111–119.
    1. Forsberg BC, Petzold MG, Tomson G, P. A. Diarrhoea case management in low- and middle-income countries--an unfinished agenda. Bull World Health Organ. 2007;85:42–48.
    1. Editorial The world's forgotton children. Lancet. 2003;361:1–1. doi: 10.1016/S0140-6736(03)12101-0.
    1. Organization WH, The Canadian Coalition for Global Health Research Canadian International Development Agency German Agency for Technical Cooperation (GTZ) Bridging the "Know-Do" Gap: Meeting on Knowledge Translation in Global Health: 2005/10/10. 2005.
    1. Health CI. The CIHR Knowledge Translation Strategy 2004-2009: Innovation in Action. 2004.
    1. DeRoeck D, Clemens JD, Nyamete A, Mahoney RT. Policymakers' views regarding the introduction of new-generation vaccines against typhoid fever, shigellosis and cholera in Asia. Vaccine. 2005;23:2762–2774. doi: 10.1016/j.vaccine.2004.11.044.
    1. Gilroy K, Kuszmerski NWP. Lessons learned in a pilot introduction of zinc treatment for childhood diarrhea in Bougouni District, Mali. United State Agency for International Development; 2005.
    1. Organization WH, Fund UNC. Global Immunization Vision and Strategy, 2006-2015. World Health Organization, Department of Immunization, Vaccines and Biologicals; 2005.

Source: PubMed

3
Se inscrever